Coding and non-coding transcriptome of mesial temporal lobe epilepsy: Critical role of small non-coding RNAs

James D. Mills, Erwin A. van Vliet, Bei Jun Chen, Michael Janitz, Jasper J. Anink, Johannes C. Baayen, Sander Idema, Sasha Devore, Daniel Friedman, Beate Diehl, Maria Thom, Catherine Scott, Roland Thijs, Eleonora Aronica, Orrin Devinsky*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Our understanding of mesial temporal lobe epilepsy (MTLE), one of the most common form of drug-resistant epilepsy in humans, is derived mainly from clinical, imaging, and physiological data from humans and animal models. High-throughput gene expression studies of human MTLE have the potential to uncover molecular changes underlying disease pathogenesis along with novel therapeutic targets. Using RNA- and small RNA-sequencing in parrallel, we explored differentially expressed genes in the hippocampus and cortex of MTLE patients who had undergone surgical resection and non-epileptic controls. We identified differentially expressed genes in the hippocampus of MTLE patients and differentially expressed small RNAs across both the cortex and hippocampus. We found significant enrichment for astrocytic and microglial genes among up-regulated genes, and down regulation of neuron specific genes in the hippocampus of MTLE patients. The transcriptome profile of the small RNAs reflected disease state more robustly than mRNAs, even across brain regions which show very little pathology. While mRNAs segregated predominately by brain region for MTLE and controls, small RNAs segregated by disease state. In particular, our data suggest that specific miRNAs (e.g., let-7b-3p and let-7c-3p) may be key regulators of multiple pathways related to MTLE pathology. Further, we report a strong association of other small RNA species with MTLE pathology. As such we have uncovered novel elements that may contribute to the establishment and progression of MTLE pathogenesis and that could be leveraged as therapeutic targets.

Original languageEnglish
Article number104612
JournalNeurobiology of Disease
Volume134
DOIs
Publication statusPublished - Feb 2020

Cite this